Valneva SE
VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.41
Price-0.86%
-$0.09
1Y
Price
Market Cap
$821.449m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$196.327m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$67.041m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.92
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$186.432m
$472.625m
Assets$286.193m
Liabilities$196.924m
DebtDebt to Assets
41.7%
-4.7x
Debt to EBITDAFree Cash Flow
-$34.389m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company